Matica Reports on Recent Market Activity

2017-12-27 / @thenewswire

(TheNewswire)

December 27, 2017 / TheNewswire / – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) at the request of the Investment Industry Regulatory Organization of Canada, confirms that its management is unaware of any material change to the company or its business that would account for the recent increase in market activity.

Management is pleased to report that management of RoyalMax Biotechnology Canada Inc. (“RoyalMax”) has informed Health Canada of a proposed January 26th completion date of the Dorval facility. Once the facility is completed management will be submitting the Photographic-Evidence video to Health Canada to request a cultivation license.

For more information on Matica please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

/s/Boris Ziger

Boris Ziger, CEO & Chairman

The Company’s filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935

E-mail: info@maticaenterprises.com

Website: www.maticaenterprises.com

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

The CSE has not reviewed, approved or disapproved the content of this press release.